9RVT image
Deposition Date 2025-07-08
Release Date 2026-04-08
Last Version Date 2026-04-22
Entry Detail
PDB ID:
9RVT
Keywords:
Title:
ACE2 extracellular domain in complex with the macrocyclic peptide GR1.4
Biological Source:
Source Organism(s):
Expression System(s):
Method Details:
Experimental Method:
Resolution:
2.39 Å
R-Value Free:
0.29
R-Value Work:
0.24
R-Value Observed:
0.24
Space Group:
P 1 21 1
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Processed angiotensin-convert
Gene (Uniprot):ACE2
Chain IDs:A, B, D, G
Chain Length:609
Number of Molecules:4
Biological Source:Homo sapiens
Protein Blast
Polymer Type:polypeptide(L)
Molecule:macrocyclic peptide GR1.4
Chain IDs:C, E, F, H
Chain Length:14
Number of Molecules:4
Biological Source:synthetic construct
Primary Citation
Yeast Display Technology Enables Rapid Discovery of Low-Nanomolar Macrocyclic Peptide Inhibitors of Human Angiotensin-Converting Enzyme 2.
J. Med. Chem. 69 7689 7708 (2026)
PMID: 41875055 DOI: 10.1021/acs.jmedchem.5c02876

Abstact

Macrocyclic peptides (MPs) are valuable molecular formats for drug development, bridging small molecules and larger biologics due to their favorable pharmacological properties. Here, we describe the discovery of low-nanomolar inhibitors of human angiotensin-converting enzyme 2 (hACE2) by quantitatively screening millions of structurally diverse disulfide-cyclized peptide ligands using yeast display technology. The most potent yeast-encoded "one-ring" and "two-ring" MP inhibit hACE2 with K(i) values of 1.9 and 1.5 nM, respectively. These inhibitory potencies are comparable to those of other cyclic peptides discovered using well-established in vitro display technologies. Crystal structures of the two MPs in complex with hACE2 reveal the adoption of either a rigid beta-hairpin or a cysteine-stabilized alpha-helix/alpha-helix motif. Both MPs exhibit binding modes distinct from those of previously reported inhibitors. Thus, yeast display is a valid technology to rapidly generate MPs with desired binding properties for the development of potential therapeutics.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback